RARE

Ultragenyx Pharmaceutical Inc

Jun 15 • 04:00PM ET

25.38

+1.03 4.23 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: BMRN RYTM KRYS MIRM PTCT IONS ALNY INCY VRTX KOD

| Held by: XBI VTI VB VBK VXF IBB IWP SCHA IWR IWF

Index	-	P/E	-	EPS (ttm)	-6.11	Insider Own	8.96%	Shs Outstand	98.00M	Perf Week	17.55%
Market Cap	2.50B	Forward P/E	-	EPS next Y	-0.70	Insider Trans	-1.58%	Shs Float	89.67M	Perf Month	-1.63%
Enterprise Value	3.29B	PEG	-	EPS next Q	-1.22	Inst Own	97.70%	Short Float	16.40%	Perf Quarter	16.32%
Income	-609.36M	P/S	3.73	EPS this Y	23.11%	Inst Trans	4.73%	Short Ratio	8.20	Perf Half Y	-29.89%
Sales	669.43M	P/B	-	EPS next Y	84.40%	ROA	-46.73%	Short Interest	14.70M	Perf YTD	10.35%
Book/sh	-2.41	P/C	5.94	EPS next 5Y	-	ROE	-656.54%	52W High	42.37 -40.10%	Perf Year	-32.30%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	16.78% -13.72%	ROIC	-68.31%	52W Low	18.29 38.76%	Perf 3Y	-48.06%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.81% 19.95%	Gross Margin	78.49%	Volatility	4.45% 4.89%	Perf 5Y	-74.63%
Dividend TTM	-	EV/Sales	4.91	EPS Y/Y TTM	-3.82%	Oper. Margin	-83.92%	ATR (14)	1.13	Perf 10Y	-59.48%
Dividend Ex-Date	-	Quick Ratio	1.85	Sales Y/Y TTM	13.33%	Profit Margin	-91.03%	RSI (14)	59.98	Recom	1.32
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	-17.21%	SMA20	9.36%	Beta	0.37	Target Price	52.05
Payout	-	Debt/Eq	-	Sales Q/Q	-2.36%	SMA50	5.23%	Rel Volume	0.82	Prev Close	24.35
Employees	1371	LT Debt/Eq	-	Earnings	May 05 AMC	SMA200	-6.33%	Avg Volume	1.79M	Price	25.38
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.67% -14.03%	Trades		Volume	1,479,242	Change	4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-26	Downgrade	Goldman	Buy → Neutral	$25
Oct-20-25	Initiated	Wells Fargo	Overweight	$65
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral

Show Previous Ratings

Jun-03-26 04:30PM	Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-22-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-26 04:30PM	Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference (GlobeNewswire)
08:30AM	Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary (Moby)
May-05-26 04:07PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-26 08:00AM	Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-24-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Mar-30-26 08:30AM	Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy (GlobeNewswire)
03:41AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-24-26 09:36AM	Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls (The Fly) -8.73%
Mar-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 06:17AM	Evotec, Vistagen lay off staff; Immutep shares collapse on study failure (BioPharma Dive)
Mar-12-26 08:30AM	Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency (GlobeNewswire)
04:18AM	Loading…
04:18AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-11-26 09:00AM	LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Mar-04-26 09:00AM	LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE (PR Newswire)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Feb-24-26 10:19AM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Feb-23-26 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
08:30AM	Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Feb-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 12:23PM	Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) (Insider Monkey)
Feb-14-26 01:29AM	Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A (Insider Monkey)
Feb-13-26 01:21PM	Why Is Ultragenyx Stock Sinking Friday? (Benzinga) -12.68%
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
08:30AM	Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary (Moby)
05:08AM	Ultragenyx cuts jobs as it seeks path to profit in 2027 (BioPharma Dive)
12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
08:14PM	Loading…
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks)
09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
07:37AM	Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall (Insider Monkey)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart) +15.52%
04:05PM	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
03:58PM	Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today (Motley Fool)
12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
08:11AM	Company News for Dec 30, 2025 (Zacks)
06:17AM	S&P Futures Tread Water Ahead of FOMC Meeting Minutes (Barchart)
Dec-29-25 04:21PM	These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com) -42.32%
03:34PM	Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today (Motley Fool)
01:18PM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com)
01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch)
08:30AM	Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Dec-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 07:44AM	Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Dec-04-25 11:30AM	Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-28-25 11:57AM	Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook (Insider Monkey)
Nov-24-25 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-21-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Nov-10-25 08:19PM	Morgan Stanley Reaffirms "Buy" Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
12:10AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 05:30PM	Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
04:01PM	Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences (GlobeNewswire)
Oct-30-25 08:00AM	Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups (GlobeNewswire)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-28-25 04:30PM	Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-24-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
Oct-17-25 09:16AM	Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Oct-08-25 12:57AM	Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Oct-03-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 09:45AM	Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline (Insider Monkey)
Sep-30-25 04:05PM	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire)
04:00AM	Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Sep-29-25 08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
Sep-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 09:17AM	Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? (Insider Monkey)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ph.D.Dr. Emil D. Kakkis M.D.

Executive VP of Corporate Strategy & CFOMr. Howard Horn

Chief Legal Officer & Executive VP of Corporate AffairsMs. Karah Herdman Parschauer J.D.

Executive VP & Chief Commercial OfficerMr. Erik Harris M.B.A.

Chief Medical Officer & Executive VPDr. Eric Crombez M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Corazon (Corsee) D.	Director	Jun 15 '26	Sale	25.05	2,000	50,100	21,095	Jun 15 06:50 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 15 '26	Sale	24.62	1,899	46,753	94,462	Jun 15 06:46 PM
KARAH PARSCHAUER	Officer	Jun 15 '26	Proposed Sale	24.35	3,799	92,506		Jun 15 04:50 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	25.05	2,000	50,100		Jun 15 04:12 PM
Horn Howard	Chief Financial Officer	Jun 01 '26	Sale	23.77	4,653	110,602	105,689	Jun 01 07:11 PM
HOWARD HORN	Officer	Jun 01 '26	Proposed Sale	23.77	4,653	110,602		Jun 01 04:08 PM
SULIMAN SHEHNAAZ	Director	May 18 '26	Sale	25.12	5,740	144,189	27,951	May 18 06:41 PM
SHEHNAAZ SULIMAN	Director	May 18 '26	Proposed Sale	25.12	5,740	144,189		May 18 04:50 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '26	Sale	24.96	344	8,586	111,189	May 06 02:51 PM
Horn Howard	Chief Financial Officer	May 01 '26	Sale	24.90	4,683	116,607	110,342	May 04 05:35 PM
HOWARD HORN	Officer	May 01 '26	Proposed Sale	24.90	4,683	116,607		May 01 04:06 PM
Horn Howard	Chief Financial Officer	Apr 01 '26	Sale	20.97	4,683	98,203	80,351	Apr 02 06:19 PM
HOWARD HORN	Officer	Apr 01 '26	Proposed Sale	20.97	4,683	98,203		Apr 01 04:12 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 06 '26	Sale	21.40	6,018	128,785	70,328	Mar 10 04:51 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 10 '26	Sale	22.67	3,508	79,526	66,820	Mar 10 04:51 PM
KARAH PARSCHAUER	Officer	Mar 10 '26	Proposed Sale	22.67	3,508	79,526		Mar 10 04:42 PM
KARAH PARSCHAUER	Officer	Mar 06 '26	Proposed Sale	21.40	6,018	128,775		Mar 06 05:28 PM
Pinion John Richard	See Remarks	Mar 02 '26	Sale	22.80	10,029	228,661	110,026	Mar 03 07:09 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 02 '26	Sale	22.80	10,539	240,289	89,515	Mar 03 07:08 PM
KAKKIS EMIL D	President & CEO	Mar 02 '26	Sale	22.80	54,404	1,240,411	658,994	Mar 03 07:06 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 02 '26	Sale	22.80	8,135	185,478	76,346	Mar 03 06:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 02 '26	Sale	22.80	1,632	37,210	48,670	Mar 03 06:51 PM
Horn Howard	Chief Financial Officer	Mar 02 '26	Sale	22.70	8,409	190,914	86,669	Mar 03 06:50 PM
Horn Howard	Chief Financial Officer	Mar 03 '26	Sale	22.40	1,635	36,624	85,034	Mar 03 06:50 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 02 '26	Sale	22.80	7,029	160,261	76,301	Mar 03 06:49 PM
HOWARD HORN	Officer	Mar 03 '26	Proposed Sale	22.40	1,635	36,624		Mar 03 04:41 PM
HOWARD HORN	Officer	Mar 02 '26	Proposed Sale	22.54	3,119	70,302		Mar 02 05:08 PM
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM
Horn Howard	Chief Financial Officer	Oct 13 '25	Sale	31.51	7,942	250,252	98,227	Oct 14 12:15 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 18 '25	Sale	29.17	64	1,867	50,242	Sep 19 06:23 PM
KARAH PARSCHAUER	Officer	Sep 12 '25	Proposed Sale	31.17	2,450	76,366		Sep 12 04:17 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Sep 12 '25	Sale	31.17	2,450	76,366	73,271	Sep 12 04:11 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 05 '25	Sale	31.39	84	2,637	50,306	Sep 08 02:01 PM
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your Finviz experience